Protana is a leading protein sequence analysis, bioinformatics and drug target characterization company. These technologies will accelerate the identification of new potential pharmaceuticals and diagnostic tests.
Proteomics is the next wave of molecular medicine after genomics.
Proteomics, the large-scale study of protein structures, interactions and pathways, should lead us to new drug targets and diagnostic tests. This is MDS's second initiative in the emerging proteomics area. In February 1999, MDS formed a research collaboration with the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto to support research in the area of proteomics focused on protein-protein interactions, an area of increasing interest to pharmaceutical companies for drug discovery and development. MDS Inc., is a broad-based, international health and life sciences company. Its core purpose is to make a distinctive contribution to the health and well-being of people.